In addition, the high baseline level of sPD-L1, decreased level of sPD-L1 after RT and some other clinical factors, such as IDH-1 WT tumors, GBMs, tumors located in the brainstem and tumors with a Ki-67 expression rate > 27.5%, were demonstrated to be related to poor prognosis in glioma patients. This evidence concerns the gene SPDL1 and central nervous system cancer.